WIRE)–Sorin Group, a global medical device
company and a leader in the treatment of cardiovascular diseases, announced
today at Heart Rhythm 2012, the Heart Rhythm Society’s 33rd Annual Scientific
Sessions, FDA approval and commercial launch for a full portfolio of pacing,
defibrillation and left ventricular leads. Designed for effective electrical
performance and durability, each of the three lead series – TILDA pacing leads,
VIGILA defibrillation leads and CELERITY left ventricular leads – include
multiple sizes and features to enable physicians to match their implant
preferences with individual patient needs.
In addition to a flexible silicone lead body, steroid
eluting tips that reduce inflammation, and iridium fractal coated electrodes
with proven electrical performance1, each lead family offers its own additional
- TILDA pacing leads include a flexible lead body and distal
tip and are designed for easy implantation and predictable performance.
- VIGILA defibrillation leads feature a symmetrical lead body
and thick outer insulation. Convex shock coils embedded in silicone insulation
are engineered to minimize tissue in-growth.
- CELERITY left ventricular leads have a flexible co-radial
body, and are designed to facilitate access and ensure stability in targeted
pacing sites regardless of patients’ coronary venous anatomies.
“Sorin Group is bringing important new implantable heart
rhythm and heart failure systems to the United States, an important and growing
market for Sorin Group. The VIGILA, TILDA and CELERITY leads are important
additions that will help the U.S.
physicians manage their patients,” said Stefano Di Lullo, Sorin Group, President
of the CRM Business Unit. “We’ve received tremendous feedback from physicians
in other international markets about the reliability of these leads, and we are
committed to continuing to deliver outstanding technologies to enhance clinical
performance and patient outcomes in the United States and throughout the
About Sorin Group
Sorin Group (www.sorin.com) is a global, medical device company and a
leader in the treatment of cardiovascular diseases. The Company develops,
manufactures, and markets medical technologies for cardiac surgery and for the treatment
of cardiac rhythm disorders. With 3,750 employees worldwide, Sorin Group
focuses on three major therapeutic areas: cardiopulmonary bypass
(extracorporeal circulation and autotransfusion systems), cardiac rhythm
management, and heart valve repair and replacement. Every year, over one
million patients are treated with Sorin Group devices in more than 80
For more information, please visit www.sorin.com.